On April 14, 2026 RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a patented, FDA-cleared drug-delivery device, reported that a clinical data abstract submitted by experts from Moffitt Cancer Center was presented at the 2026 Society of Interventional Radiology (SIR) Annual Scientific Meeting in Toronto, Canada.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The abstract, entitled "What PET/CT Reveals After Transarterial Microperfusion for Pancreatic Cancer," was presented on April 13, 2026 by a multidisciplinary team of experts, including Dr. Mustafa Al-Roubaie, an Interventional Radiologist at Moffitt Cancer Center and member of RenovoRx’s Medical Advisory Board.
The abstract examined the effectiveness of local, targeted intra-arterial chemotherapy administration using RenovoRx’s patented TAMP (Trans-Arterial Micro-Perfusion) therapy platform. By delivering chemotherapy directly near the tumor site, TAMP helps to overcome the poor vascularity typical of solid tumors like locally advanced pancreatic cancer (LAPC), where intravenous chemotherapy is often less effective. Additionally, the abstract assessed the potential application of metabolic imaging, FDG (fluorodeoxyglucose) PET/CT, in evaluating therapeutic outcomes following targeted intra-arterial drug-delivery via TAMP in patients with refractory disease.
The study concluded that TAMP is a promising approach for localized delivery of chemotherapeutic agents for the treatment of solid tumors such as LAPC, offering the potential for enhanced therapeutic drug-delivery with reduced systemic toxicity. Metabolic imaging further demonstrated dramatic reductions in FDG avidity, suggesting treatment response even when tumor size changed minimally. Eight cycles of intra-arterial chemotherapy were administered over 2 months, using the TAMP therapy platform, which is enabled by the Company’s RenovoCath device. Post-treatment imaging results indicated that PET/CT may detect early treatment response before anatomical changes occur.
"Patients diagnosed with LAPC face a challenging prognosis, due in part to a dense, hypovascular stroma that can restrict the effectiveness of traditional systemic (namely intravenous) chemotherapy," said Dr. Al-Roubaie. "Systemic chemotherapeutic administration is often associated with considerable toxicity and suboptimal tumor penetration. The TAMP therapy platform aims to increase local drug concentration directly near the tumor site while reducing systemic exposure."
Dr. Al-Roubaie continued, "These findings support RenovoRx’s TAMP therapy platform and its ability for local intra-arterial chemotherapeutic delivery directly near the tumor site and the potential for reduced toxicity for patients. These findings may complement RenovoRx’s ongoing Phase III TIGeR-PaC clinical trial evaluating the company’s lead drug-device product candidate (intra-arterial gemcitabine delivered via RenovoCath, known as IAG) for the treatment of LAPC."
About RenovoCath
Based on its FDA clearance, RenovoCath is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to select sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use ("IFU"), please see: IFU-10004-Rev.-G-Universal-IFU.pdf.
(Press release, Renovorx, APR 14, 2026, View Source [SID1234664386])